Related Experiment Videos
Withdrawal-emergent dyskinesia in a patient on risperidone undergoing dosage reduction
1SUNY Health Science Center at Syracuse, Department of Psychiatry, Syracuse 13210, USA.
Summary
A patient experienced withdrawal-emergent dyskinesia after reducing risperidone for schizophrenia. This suggests a potential link between risperidone and tardive dyskinesia risk.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Schizophrenia is a chronic mental disorder often treated with antipsychotic medications.
- Risperidone is a commonly prescribed second-generation antipsychotic.
- Antipsychotic medications carry risks, including movement disorders.
Observation:
- A 23-year-old male with paranoid schizophrenia experienced dyskinesia.
- The dyskinesia emerged during a dose reduction of risperidone.
- This specific movement disorder is termed withdrawal-emergent dyskinesia.
Findings:
- The case highlights a potential association between risperidone and the development of dyskinesia.
- Withdrawal-emergent dyskinesia may indicate an increased future risk of tardive dyskinesia.
- The study discusses the specific implications of this adverse event.
Implications:
- Clinicians should be aware of the potential for dyskinesia during risperidone dose reduction.
- This case may inform risk assessment for tardive dyskinesia in patients on risperidone.
- Further research may be needed to clarify the relationship between risperidone and movement disorders.